Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study

Lancet

Volumn 352, Issue 9133, 1998, Pages 1016-1021

  Hawkey, C J ^a   Tulassay, Z ^b   Szczepanski, L ^c   Van Rensburg, C J ^d   Filipowicz Sosnowska, A ^e   Lanas, A ^f   Wason, C M ^g   Peacock, R A ^g   Gillon, K R W ^g  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b II Sz Belgyogyaszati Klinika   (Hungary)

^c School of Medicine   (Poland)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e INSTITUTE OF RHEUMATOLOGY   (Poland)

^f HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^g Astra Clinical Research Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; DICLOFENAC; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; UREA;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BREATH ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DYSPEPSIA; ENDOSCOPY; FEMALE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ULCER HEALING;

EID: 0032569495     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)04206-8     Document Type: Article

References (33)

1. 1 Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associate with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-78.
2. 2 Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and performation associated with individual non steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72.
3. 3 Henry D, Lim LL-Y, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-66.
4. 4 NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-69.
5. 5 Kim JG, Graham DY, and the Misoprostol Study Group. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. Am J Gastroenterol 1994; 89: 203-07.
6. 6 Cullen DJE, Hawkey GM, Greenwood DC, et al. Peptic ulcer bleeding: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs. Gut 1997; 41: 459-62.
7. 7 Aalykke C, Lauritsen JM, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K. Helicobacter pylori: a risk factor in NSAID-related bleeding peptic ulcer - a prospective case control study. Gastroenterology 1997; 122: A51.
8. 8 Ekström P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. Scand J Gastroenterol 1996; 31: 753-58.
9. 9 Hawkey CJ, Jeffrey AK, Szczepnski L, et al for the OMNIUM Study Group. A comparison of omeprazole and misoprostol for treating and preventing ulcers associated with non steroidal anti-inflammatory drugs. N Engl J Med 1998; 338: 727-34.
10. 10 Yeomans ND, Tulassay Z, Juhasz L, et al for the ASTRONAUT Study Group. A comparison of omeprazole and ranitidine for treating and preventing ulcers associated with non steroidal anti-inflammatory drugs. N Engl J Med 1998; 338: 719-26.
11. 11 Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-52.
12. 12 Hudson N, Balsitis M, Filipowicz B, Hawkey CJ. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34: 748-51.
13. 13 Jorde R, Bostad L, Burhol PG, Asymptomatic gastric ulcer, a follow up study in patients with previous gastric ulcer disease. Lancet 1986; i: 119-21.
14. 14 Malfertheiner P, Dominguez-Munoz JE, Heckenmuller H, Neubrand M, Fischer HP, Sauerbruch T. Modified rapid urease test for detection of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1996; 8: 53-56.
15. 13C-urea breath test for the detection of Helicobacter pylori. Eur J Gastroenterol Hepatol 1991; 3: 905-11.
16. 16 Graham DY, Lew DM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-96.
17. 17 World Health Organisation Collaborating Centre for Drug Statistics Methodology. Guidelines for defined daily doses. Oslo: World Health Organization, 1991.
18. 18 Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs. N Engl J Med 1996; 334: 1435-39.
19. 19 Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in non-steroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997; 112: 1817-22.
20. 20 Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one week triple therapies combining omeprazole with two antimicrobials: the MACH 1 study. Helicobacter 1996; 1: 138-44.
21. 21 Working Party of the European Helicobacter pylori Study Group. Guidelines for clinical trials in Helicobacter pylori infection. Gut 1997; 41 (suppl2): S1-23.
22. 22 Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Therap 1997; 11(suppl): 43-53.
23. 23 Bell GD, Powell KU, Burridge SM, et al. Reinfection or recrudescence after apparently successful eradication of Helicobacter pylori infection: implications for treatment of patients with duodenal ulcer disease. Q J Med 1993; 86: 375-82.
24. 24 Caselli M, Pazzi P, LaCorte R, Aleotti A, Trevisani L, Stabellini G. Campylobacter-like organisms, non-steroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis. Digestion 1989; 44: 101-04.
25. 25 Hogben CAM, Schanker LS, Tocco DJ, Brodie BB. Absorption of drugs from the stomach II. Hum J Pharmacol Exp Ther 1957; 120: 540-45.
26. 26 Chan FKL, Sung JJY, Chung SCS, et al. Randomised eradication of H pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975-79.
27. 27 Jensen DM, Cheng S, Kovacs TOG, et al. A controlled study of ranitidine for the prevention of recurrent haemorrhage from duodenal ulcer. N Engl J Med 1994; 330: 382-86.
28. 28 Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 1993; 23: 939-42.
29. 29 Labenz J, Borsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 1994; 55: 19-23.
30. 30 Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non steroidal anti-inflammatory drugs. Ann Intern Med 1995; 123: 241-49.
31. 31 Chan FKL, Sung JY, Suen R, et al. Eradication of H pylori versus maintenance acid suppression to prevent recurrent ulcer haemorrhage in high risk NSAID users: a prospective randomised study. Gastroenterology 1998; 114: A87.
32. 32 Malfertheiner P. Current European concepts in the management of Helicobacter pylori infection: the Maastricht consensus report. Gut 1997; 41: 8-13.
33. 33 Bianchi Porro G, Parente F, Imbesi V, Montrone F, Caruso I. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in long term NSAID users: response to omeprazole dual therapy. Gut 1996; 39: 22-26.